Global Market for Pain Management Drugs and Devices

Dec 2023| HLC026G| BCC Publishing

Report Highlights

The global market for pain management drugs and devices is expected to increase from $84.6 billion in 2023 to $109.9 billion by the end of 2028, with a compound annual growth rate (CAGR) of 5.4% during the forecast period of 2023-2028.

Report Includes

  • 44 data tables and 37 additional tables
  • An overview of the global market for pain management drugs and devices
  • Estimates of the market size and analyses of global market trends with data from 2020-2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Assessment of pain, history of pain and pain management, and information on physical pain treatment modalities and psychological pain therapies.
  • Coverage of emerging technologies in the pain management market, an assessment of technology advances in opioid drugs, as well as in non-narcotic drugs, which has revolutionized pain management by providing practical alternatives to opioids.
  • Assessment of factors driving the industry's growth, including market opportunities and restraints
  • Examination of product categories, clinical trials, new regulatory requirements and relevant patents
  • Coverage of market trends in undertreatment issues, professional issues, managed care pain issues, new therapies, product pipelines, generics, pain research and drug delivery
  • Company profiles of major players within the industry, including Abbott Laboratories, AbbVie Inc., Assertio Holdings Inc., Grünenthal GmbH, and Johnson & Johnson

Report Scope

The current report provides detailed analysis of the market for pain management drugs and devices. It highlights the current and future market potential of pain management drugs and devices and gives a detailed analysis of the market’s drivers, restraints and challenges. The report also covers market projections for 2028 and provides market rankings for key market players. It also covers the competitive environment and regulatory landscape, and it details the market share of pain management drugs and devices based on product and application. Based on products, the global pain management drugs and devices market is segmented into pharmaceuticals and medical devices. Based on applications, the market is segmented into post-operative pain, neuropathic pain, cancer pain, migraine/headache, musculoskeletal pain and other applications. The report includes company profiles of the key players with detailed information about their business segments, financials, product portfolios and recent developments.

The market has been divided by geography into North America, Europe, Asia-Pacific and the Rest of the world. The North American region comprises countries such as the U.S. and Canada; Europe includes countries Germany, U.K., Italy, France and the Rest of Europe; Asia-Pacific includes countries China, India, Japan and the Rest of Asia-Pacific. For market estimates, data has been provided for 2020 and 2021, which serve as the historical years; 2022 is the base year; and forecast data is given for 2028.

Not covered in the report are drugs or devices that relieve pain by treating the specific condition or disorder. These include treatments for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or other similar diseases. Only those disease-specific treatments that involve a relief of the pain symptoms associated with the respective condition are included.

Here is a comparison of a treatment for a disease (in this case, rheumatoid arthritis) that naturally relieves symptoms vs. a treatment for the relief of the pain associated with the disease:

  • Enbrel: Indicated for the treatment of moderate-to-severe rheumatoid arthritis.
  • Celebrex: Indicated for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and the management of acute pain.

Frequently Asked Questions (FAQs)

The global pain management market was estimated at $80.9 billion in 2022. The market is projected to reach $109.9 billion in 2028, growing at a CAGR of 5.4% during the forecast period.
Key drivers of the pain management market are the rising prevalence of chronic pain and related conditions and the growing incidence of road accidents and surgical procedures.
The pain management market is segmented based on product, application, and region.
The pharmaceuticals segment will dominate the market by the end of 2028.
North America holds the highest share of the market.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $80.9 billion
Market size forecast $109.9 billion
Growth rate CAGR of 5.4% for the forecast period of 2023-2028
Units considered $ Millions
Segments covered Product, Application
Regions covered North America, Europe, Asia-Pacific, Rest of the World (RoW)
Countries covered U.S., Canada, U.K., Germany, Italy, France, Rest of Europe, China, India, Japan, Rest of Asia-Pacific
Key Market Drivers
  • Rising Prevalence of Chronic Pain and Related Conditions
  • Increasing Aging Population
  • Growing Incidence of Road Accidents and Surgical Procedures
Companies studied
  • ABBOTT
  • ABBVIE INC.
  • ASSERTIO HOLDINGS INC.
  • ASTRAZENECA PLC
  • BOSTON SCIENTIFIC CORP.
  • ELI LILLY AND CO.
  • ENDO INTERNATIONAL PLC
  • ENOVIS CORP.
  • GSK PLC.
  • GRUNENTHAL GMBH
  • JOHNSON & JOHNSON SERVICES INC.
  • MEDTRONIC
  • NOVARTIS INTERNATIONAL AG
  • VERTEX PHARMACEUTICALS
  • VIATRIS INC.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Global Market for Pain Management Drugs and Devices171Free
Chapter- 1: Introduction4Free
Chapter- 2: Summary and Highlights4Free
Chapter- 3: Market Overview14Free
Chapter- 4: Market Dynamics9Free
Chapter- 5: Market Breakdown by Product 36Free
Chapter- 6: Market Breakdown by Application22Free
Chapter- 7: Market Breakdown by Region13Free
Chapter- 8: ESG Development11Free
Chapter- 9: Emerging Technologies3Free
Chapter- 10: Clinical Trials and Patent Analysis8Free
Chapter- 11: Competitive Intelligence4Free
Chapter- 12: Company Profiles42Free
Chapter- 13: Appendix: Acronyms1Free
Published - Aug-2017| Analyst - Melissa Elder| Code - HLC026F

Report Highlights

The global market for pain management will grow from nearly $36.1 billion in 2017 to $52.0 billion by 2022, with a compound annual growth rate (CAGR) of 7.6% for the period of 2017-2022.

Report Includes 

  • An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers
  • Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Examination of product categories, use of products, and the competitive landscape
  • Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations
  • Discussion of new regulatory requirements
  • Comprehensive company profiles of major players in the industry
Published - Sep-2015| Analyst - Melissa Elder| Code - HLC026E

Report Highlights

Market for global pain management pharmaceuticals and devices by revenue at manufacturers’ sales levels is projected to grow from $36.6 billion in 2014 to nearly $37.8 billion in 2015 and $44.3 billion in 2020, with a compound annual growth rate (CAGR) of 3.2% between 2015 and 2020.

Report Includes

  • An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers.
  • Analyses of global market trends, with data from 2013 and 2014; estimates for 2015, and projections of CAGRs through 2020.
  • Examination of product categories, use of products, and the competitive landscape.
  • Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations.
  • Discussion of new regulatory requirements.
  • Comprehensive company profiles of major players in the industry.
Published - Jan-2013| Analyst - Melissa Elder| Code - HLC026D

Report Highlights

The market for pain management drugs and devices was valued at $35.4 billion in 2012. Total market valued is expected to reach $41.5 billion in 2017 after increasing at a five-year compound annual growth rate of 3.2%.

Report Includes

  • An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers.
  • Analyses of global market trends, with data from 2012, and projections of compound annual growth rates (CAGRs) through 2017.
  • Examination of product categories, use of products, and the competitive landscape.
  • Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations.
  • Discussion of new regulatory requirements.
  • Comprehensive company profiles of major players in the industry.
Published - Aug-2009| Analyst - Melissa Elder| Code - HLC026C

Report Highlights

  • The global market for pain management pharmaceuticals and devices amounted to $19.1 billion in 2008 and is expected to increase to $32.8 billion in 2013. The compound annual growth rate (CAGR) for the 5-year period is projected at 11.5%.
  • The pharmaceuticals segment dominated the market at $17.6 billion in 2008. That figure is expected to increase to $30.2 billion in 2013, for a CAGR of 11.5%.
  • The devices segment of the market generated $1.48 billion in sales in 2008 and is projected to increase to $2.5 billion in 2013, for a CAGR of 11.4%.
Published - Jun-2007| Analyst - Alpita Shah| Code - HLC026B

Report Highlights

  • The global pain-management market is worth around $30.9 billion in 2007. It is forecasted to grow at a compound annual growth rate (CAGR) of 5.63% to reach $40.6 billion by the end of the forecast period, 2012.
  • The pharmaceuticals segment of the pain-management market is valued at $29 billion in 2007. It will be worth $38 billion by 2012 at a CAGR of 5.6%.
  • In 2007, market revenue from the medical devices segment is around $1.9 billion. This segment is predicted to grow at a CAGR of 6.5% to reach $2.6 billion by the end of 2012.
Published - Aug-2000| Analyst - Mary Anne Crandall| Code - HLC026A

Report Highlights

  • This report presents the forecast of the market for pain management through the year 2005. By 2005, it is anticipated that revenues will likely reach $32 billion, growing at an average annual rate of almost 12%.
  • Pain management pharmaceuticals currently hold the largest market revenue position, representing 97% and accounting for $16 billion of the total in 1999. Pharmaceuticals have long been the mainstay of pain management and it is anticipated that they will remain the largest market share throughout the forecast period.
  • Pain management devices account for 3%, representing $418.5 million in 1999. It is anticipated that the device segment will gain market revenue position due to technological advancements and a gradually declining cost increasing demand for current technologies

Global Market for Pain Management Drugs and Devices

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS